	_	numberEL230529	738US			
Date of Deposit	7-	03-03				
		or fee is being deposited wi			-	
service under 37 VA 22313-1450		on the date indicated above a	^			
QUE	276	THOMAS	65	ullen	Skan	red
Printed Nam	e	Signature	/			

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Douglas James Allen et al.

For: 2-Methyl-Thieno-Benzodiazepine Formulation)

Docket No.: X-11666C

PRELIMINARY AMENDMENT

Commissioner for Patents
P. O. Box 1450
Arlington, VA 22202-0327
Sir:

1 .

Prior to examination of the above-identified application, entry of the following preliminary amendments to the claims and specification, which are attached hereto, is respectfully requested. An Information Disclosure Statement is included herewith.

REMARKS

The cross reference in the specification has been amended to indicate that this application is a continuation application of United States Application Serial No. 10/136,887, filed May 1, 2002 which is a continuation application of United States Application Serial No. 09/509,757, filed March 29, 2000 which is a 371 of PCT/US98/20426 filed September 30, 1998 which claims priority to United States Provisional Application Number 60/060,493 filed September 30, 1997. Applicants wish to point out that United States Application Serial No. 10/136,887, filed May 1, 2002, has been allowed.

In addition, the claims have been amended as set forth in the attachment herewith pursuant to 37 C.F.R § 1.121. In particular, claims 2, 8, 9, 18-20, and 25-33 have been

cancelled. Support for the amendment to claim 1 can be found, for example, in original claim 2, and on page 3, lines 19-20. Support for the amendment to claim 4 can be found on page 33, lines 13-16 and page 34, line 32. Support for the amendments to claims 5 and 17 can be found on page 33, lines 13-16. Claim 21 was amended so as to depend upon a noncancelled claim. Support for new claim 34 can be found, for example, on page 2, lines 25-27 and page 3, lines 19-20. It is respectfully submitted that entry of the amendments submitted herewith introduces no new matter to the application.

Applicants respectfully submit that claims 1, 3-7, 10-17, 21-24, and 34 are in condition for examination. An early allowance of claims 1, 3-7, 10-17, 21-24, and 34 is kindly solicited.

Respectfully submitted,

Nelsen L. Lentz

Attorney for Applicants Registration No. 38,537

Phone: 317-276-1207

Eli Lilly and Company Patent Division P. O. Box 6288 Indianapolis, Indiana 46285

June 30, 2003